Tenapanor shows promise in Irritable bowel syndrome in phase 3 trials: claims study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-01-07 11:00 GMT | Update On 2021-01-08 08:45 GMT

Irritable bowel syndrome (IBS) is a chronic symptom-based disorder characterized by abdominal pain and altered bowel movements . Symptoms of IBS can cause considerable morbidity, impair quality of life, and impact work productivity . The financial burden of IBS is comparable with other common chronic diseases of similar prevalence, including asthma, migraine, and congestive heart failure.

Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3.

In a recent phase 3 trial recently published in The American Journal of Gastroenterology, researchers assessed the efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with constipation-predominant irritable bowel syndrome.

This multicenter, phase 3, randomized, double-blind, placebo-controlled study enrolled patients from 92 sites in the United States between November 2015 and March 2017 (last patient randomized on December 1, 2016). After a 2-week screening period, eligible patients were randomly assigned to receive tenapanor hydrochloride (hereafter referred to as tenapanor) 50 mg b.i.d. or placebo b.i.d. for 12 weeks. Patients were instructed to take 1 tablet immediately before breakfast or the first meal of the day and another tablet immediately before dinner.

Data revealed the following facts.

Of the 629 randomized patients with IBS-C, 606 (96.3%) were included in the intention-to-treat analysis set (tenapanor: n = 307; placebo: n = 299) and 533 (84.7%) completed the 12-week treatment period.
In the intention-to-treat analysis set (mean age 45 years, 81.4% women), a significantly greater proportion of patients treated with tenapanor met the primary endpoint than patients treated with placebo (27.0% vs 18.7%, P = 0.020).
Abdominal symptoms and global symptoms of IBS also improved with tenapanor (P < 0.05 vs placebo).
Diarrhea was the most commonly reported adverse event, resulting in study drug discontinuation in 6.5% and 0.7% of patients receiving tenapanor and placebo, respectively, during the 12-week treatment period.

Observing the results, the team concluded that," In conclusion, tenapanor, with its unique mechanism of action, positive impact on key symptoms and satisfaction measures, and acceptable safety profile, could offer an exciting new treatment option for patients with IBS-C."

For full article follow the link: Chey, W. D., Lembo, A. J., & Rosenbaum, D. P. (2020). Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). The American journal of gastroenterology, 115(2), 281–293. https://doi.org/10.14309/ajg.0000000000000516

Primary source: The American Journal of Gastroenterology

Article Source : The American Journal of Gastroenterology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Satabdi Saha

Dr Satabdi Saha (BDS, MDS) is a practicing pediatric dentist with a keen interest in new medical researches and updates. She has completed her BDS from North Bengal Dental College ,Darjeeling. Then she went on to secure an ALL INDIA NEET PG rank and completed her MDS from the first dental college in the country – Dr R. Ahmed Dental College and Hospital. She is currently attached to The Marwari Relief Society Hospital as a consultant along with private practice of 2 years. She has published scientific papers in national and international journals. Her strong passion of sharing knowledge with the medical fraternity has motivated her to be a part of Medical Dialogues.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Tenapanor shows promise in Irritable bowel syndrome in phase 3 trials: claims study

Similar News

Does red meat alter gut bacteria to aggravate inflammatory bowel disease?

Study Finds Yogurt and Hot Spring Baths Boost Gut Health Together

Chitinase-3-like protein 1: A novel biomarker for liver disease diagnosis and management, finds study

Destinex Liquid Biopsy Accurately Detects Early Gastric Cancer: Study Shows

Genetic testing reduces risks from chemotherapy for gastrointestinal cancer patients: Study

Food-derived compound fights inflammatory bowel disease by restoring gut balance: Study

Cholecystectomy Linked to Higher Risk of MASLD, Especially in Patients with Multiple Metabolic Risk Factors: Study

Probiotics can help or hinder gut recovery after antibiotic treatment: Study